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Abstract
Human papillomavirus (HPV) infection is the cause of cervical cancer. Integration of HPV-16 DNA in cervical cells is considered to be a
key event in the progression towards invasive cancer, but little is known about this event in anal carcinogenesis. The integration could
be a useful biomarker for cancer progression. Optimized assays are needed to determine the value of real-time detection of HPV
integration in longitudinal studies, and this approach is only possible with a high-throughput assay. The aim of this study was to develop
a new multiplex real-time PCR assay based on simultaneous ampliﬁcation of the E2 and E6 HPV open reading frames (ORFs) in order
to assess the physical status (episomal and/or integrated) of HPV-16 in anal cells of HIV-positive men. The comparative threshold (Ct)
cycle values for E2 and E6 obtained for SiHA cells and artiﬁcial mixtures of episomal and integrated DNA were as expected: similar Ct
for episomal forms and absence of E2 ampliﬁcation for integrated forms. The multiplex real-time PCR was tested in 77 consecutive
samples from individual HIV-infected patients with HPV-16 anal infection. The integration of HPV-16 was detected in 25 (32%) patients:
23 as mixed (episomal and integrated) and two as completed integrated forms. The integration occurs in the early stage of anal lesions
and was associated with the severity of the lesions (p 0.004). The multiplex real-time PCR assay developed in the course of this study
was shown to be a simple, sensitive, speciﬁc and inexpensive technique which may be applied routinely to detect HPV-16 integration.
Keywords: Anal cytology, HIV men, HPV-16 integration, human papillomavirus, physical status HPV
Original Submission: 1 March 2009; Revised Submission: 10 June 2009; Accepted: 16 June 2009
Editor: E. Gould
Article published online: 15 October 2009
Clin Microbiol Infect 2010; 16: 836–842
10.1111/j.1469-0691.2009.02964.x
Corresponding author and reprint requests: M. P. Can˜adas,
Department of Molecular Biology, General Lab, Londres 28,
08021Barcelona, Spain
E-mail: bmol@general-lab.es
*Both authors have contributed equally to this study.
Introduction
Human papillomavirus (HPV) infection is well known as
the most important cause of cervical cancer, being
preceded by precursor lesions that can be classiﬁed as
low- or high-grade squamous intraepithelial lesions (LSIL
or HSIL, respectively). Although these lesions are the
result of HPV infection, only a small proportion of infected
women will develop cervical cancer. As the clinical
outcome of these lesions cannot be predicted on the basis
of cytological assessment, different markers have been
proposed, e.g. the persistence of the infection and viral
integration [1].
The persistent infection of high-risk HPV such as HPV-16
and HPV-18 is directly associated with pre-cancerous lesions.
The HPV-16 infection is the most prevalent type found in
cervical cancer as well as in anal cancer [2]. HPV infection
remains highly prevalent and persistent among HIV-infected
patients [3,4] who have an increased risk of developing HPV-
related squamous cell cancers in the anus.
The integration of HPV-16 DNA into the host genome is
considered an important event in the progression of prema-
lignant cervical lesions to cervical cancer. Early HPV-16 DNA
integration in pre-neoplasic cervical lesions has been
reported [5–8]. During HPV infection, products of viral E6
and E7 oncoproteins are important for the process of trans-
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formation and immortalization of infected cells, causing the
development of malignant lesions. These proteins are regu-
lated by the E2 gene product which represses the transcrip-
tion of the E6 and E7 genes. The E2 open reading frame
(ORF) has been identiﬁed as the preferential site of HPV
integration, being more frequently disrupted or deleted than
other sites [9]. Therefore, the lack of control of E2 over E6
and E7 gene transcription, as a consequence of the integra-
tion process, could play a role in the progression and devel-
opment of carcinogenic lesions [7,10]. However, little is
known about this phenomenon in anal lesions of HIV-positive
patients.
Different methodologies have been used to detect inte-
grated forms, such as Southern blot analysis, two-dimensional
gel electrophoresis, ampliﬁcation by PCR and the recently
quantitative real-time PCR [8–11]. Real-time PCR tests are
based on the assumption that the episomal (not integrated)
form contains the same number of copies of both E2 and E6.
When integration occurs, disruption of the E2 gene causes a
reduction in the E2 copy number; thus, integration can be
detected by measuring the E2/E6 DNA ratio [11]. Although
integration could be a good biomarker for carcinogenic
progression, the techniques to evaluate this are time
consuming. The availability of a simple and sensitive method
to detect HPV DNA integration into the human genome
would allow routine testing in a clinical setting. The aim of
this study was to develop a new single-tube multiplex
real-time PCR to analyse the HPV-16 physical status in anal
cytological samples of HIV-1 infected men.
Patients and Methods
Study population
Between January 2005 and December 2006, all consecutive
samples from individual patients from the CARH-MEN
cohort (CAn Ruti HIV-infected MEN) with an HPV-16-posi-
tive anal infection were included. The Germans Trias i Pujol
Hospital ethical committee approved the protocol and
written informed consent was obtained from all participants
enrolled in the study.
New multiplex real-time PCR (TaqMan assay)
To study the physical status of HPV-16, a new multiplex
real-time PCR method was developed for simultaneous
ampliﬁcation of the E2 and E6 regions. This method is
based on the assumption that when the virus is integrated,
the E2 region is deleted, allowing the detection of integra-
tion as a reduced degree, or total absence, of E2 ampliﬁca-
tion. PCR primers and minor groove binder probes were
designed using Primers Express software (Applied
Biosystems, Foster City, CA, USA); the sequences and ﬂuo-
rochromes are shown in Table 1. Ampliﬁcation was opti-
mized to be performed in 25 lL, including DNA in 5 lL,
2· Universal Real-time Master mix (Applied Biosystems),
30 pmol of E2 forward and reverse primers, 6 pmol of E2
probe, 3 pmol of E6 primers and 1 pmol of E6 probe. PCR
was carried out for 45 repeat cycles at 50C for 2 min,
95C for 1 min, 55C for 1 min and 72C for 1 min in a
7300 PCR systems apparatus (Applied Biosystems).
Different physical states (episomal, integrated or both)
were identiﬁed by comparing the threshold cycle (Ct)
between E2 and E6. The same Ct was expected for episomal
forms (same amount of E6 and E2 products), an increased
E2 Ct for mixed (episomal and integrated) forms, and an
undetectable E2 Ct for integrated forms.
Control samples of HPV-DNA integration. SiHA cervical carci-
noma cells were used as control for HPV-DNA integration.
SiHA cell lines have one–two copies of integrated HPV-16
in which the E2 gene is deleted and the E6 is retained [12].
DNA extracted from four anal cell samples obtained from
asymptomatic patients with transient HPV-16 infection
(deﬁned as HPV-16) positive that were found negative for
HPV infection after two consecutive visits) was considered
to have only episomal HPV and was used as episomal con-
TABLE 1. Primer and probe seq-
uences used for real-time PCR
Primer pair Primer sequencea Primer locationb Size (bp)
E2F 5¢-GCAACGAAGTATCCTCTCCTGAA-3¢ 3358–3381 82
E2R 5¢-AAGGCGACGGCTTTGGTAT-3¢ 3419–3440
E6F 5¢-ACCGGTTAGTATAAAAGCAGACATTTTAT-3¢ 55–84 70
E6R 5¢-GCTCCTGTGGGTCCTGAAAC-3¢ 105–125
Probe
E2-Probe TTATTAGGCAGCACTTGGC-FAM 3383–3401
E6-Probe CACCAAAAGAGAACTGC-VIC 86–102
aPrimers and probes were designed based on sequences available for the HPV-16 reference strain (Gen Bank acces-
sion number NC001526).
bNumbers correspond to positions within the HPV-16 reference sequence; bp, base pairs.
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trols. Episomal HPV-16 in samples was quantiﬁed using a
standard calibration curve constructed by amplifying E6
DNA from SiHA cells at known concentrations obtained
after serial dilutions (1 · 104 to 1 · 101 copies). Artiﬁcial
mixtures, prepared by adding different SiHa DNA amounts
(c. 1 · 104, 1 · 103, 1 · 102, and 1 · 10 copies) to quanti-
ﬁed episomal samples, were used for real-time PCR devel-
opment to simulate the environment existing in clinical
samples.
Cytological diagnosis of anal samples. Anal samples were
obtained with a brush and kept in PreservCyt/ThinPrep solu-
tions. The cytological changes were classiﬁed according to
the Bethesda System: normal, ASCUS (atypical squamous
cells of uncertain signiﬁcance), LSIL or HSIL. All samples
were analysed by two cytopathologists.
HPV detection and typing. After cytological analysis, DNA was
extracted from cellular suspensions using the Qiamp Viral
DNA kit (QIAGEN, Hilden, Germany) according to the
manufacturer’s protocol. Samples were stored at )40C
until analysis. HPV detection and typing were performed in
all samples using the F-HPV typing kit (Molgentix, Spain) in
accordance with the manufacturer’s instructions. Brieﬂy,
extracted DNA was ampliﬁed using a multiplex F-HPV PCR
with a set of 15 ﬂuorochrome-labelled primers recognizing
HPV types within the E6 and E7 regions of the HPV gen-
ome. The F-HPV ampliﬁcation was performed in a ﬁnal
PCR volume of 25 lL containing 20 lL of reaction mixture
and 5 lL of extracted DNA for 35 repeat cycles of 30 s at
95C, 30 s at 64C and 30 s at 72C. Products were ana-
lysed using capillary electrophoresis on an ABI 3130 XL
genetic analyser and GeneMapper 4.0 Software (Applied
Biosystems).
Statistical analyses
A descriptive analysis was performed. Prevalence and corre-
sponding 95% conﬁdence intervals (95% CI) were calculated
for anal HPV-infection, anal HPV-16 infection and anal
cytological lesions.
Fisher’s exact test was used to assess associations
between the physical status of HPV-16 and the degree of
anal pathology. Repeatability and reproducibility of the real-
time PCR assay were assessed by calculating the coefﬁcient
of variation (CVs) of the increment of Ct (DCt) value. A p
value £0.05 was considered statistically signiﬁcant. All data
were recorded in a database program (Microsoft Access for
Windows XP, Redmont, CA, USA). Data analysis was per-
formed using the statistical software program SPSS version
15.0 (SPSS Inc., Chicago, IL, USA).
Results
Optimization of multiplex real-time PCR
The multiplex real-time PCR set up was based on titrating
different concentrations of primers and probes to obtain the
expected relative Ct values for the different physical forms.
Similar Ct values were obtained for E6 and E2 in episomal
forms (Fig. 1a). As expected, no E2 ampliﬁcation was
detected in completely integrated forms (Fig. 1b). The ampli-
ﬁcation efﬁciency of E2 and E6 with different input DNAs
was also assessed in serial dilutions of episomal samples.
Using the artiﬁcial mix with SIHA cell lines (mixed episomal/
integrated samples), the E2 Ct values increased with regard
to E6 so that a DCt could be calculated (Fig. 1c).
(a)
E2 gene 
E6 gene 
(b)
(c)
E6 gene 
E6 gene 
E2 gene 
E2 gene 
FIG. 1. (a) Real-time PCR detection of HPV-16 episomal forms in
clinical samples. E2 and E6 are present in the same amount and
ampliﬁed with the same comparative threshold (Ct). (b) Detection
of the fully integrated form. The E2 amplicon is disrupted by integra-
tion and only E6 is ampliﬁed. (c) Detection of mixed (episomal and
integrated) forms. As result of partial integration, E2 copies decrease
relative to E6, thus producing a difference in Ct [DCt].
838 Clinical Microbiology and Infection, Volume 16 Number 7, July 2010 CMI
ª2009 The Authors
Journal Compilation ª2009 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16, 836–842
The variability of E2 and E6 DCt in episomal samples was
evaluated by testing four cases in triplicate on different days;
this allowed us to assess the repeatability and reproducibility
of the assay (Table 2). Based on the values of DCt (max.
0.73 ± 0.22, min. 0.19 ± 0.15), samples with DCt values of
up to 1 were considered to be a mixed form.
The sensitivity of this method in discriminating different
HPV physical forms was assessed in artiﬁcial mixtures of
SiHa DNA in episomal DNA samples at known concentra-
tions, tested in triplicate on three different days (Table 3).
The assay was found to be sensitive enough to detect
integrated forms even if present at a concentration ﬁve
times lower than episomal forms. This ratio was found to
be maintained at concentrations of episomal forms
between 5000 and 10 copies (23 and 32 Cts, respectively),
but at higher concentrations of episomal forms (i.e. 50 000
copies), 1:5 integration was not sufﬁcient to be detected
with the assay.
Population used to test multiplex real-time PCR
HIV-infected patients (n = 269) were visited and tested for
anal HPV-16 infection which was found in 77 of them (29%,
95% CI: 23–34%). The same samples were used to assess
HPV-16 integration. In this group of HIV-infected patients
with anal HPV-16 infection, 77% (59/77, 95% CI: 66–86%)
had anal cytological abnormalities with the following cytologi-
cal diagnoses: ASCUS 22% (17/77), LSIL 41% (32/77) and
HSIL 13% (10/77). Eighteen (23%) patients had normal cyto-
logical results.
HPV-16 integration status
Integration was detected in 32% (25/77, 95%CI: 22–44%) of
HPV-16-positive samples. In 23 of these cases, integration
was found to be mixed (episomal and integrated) whereas in
two cases full integration was observed. It is important to
point out that the overall HPV-16 integration rate was 9%
(25/269, 95% CI: 6–13%).
The 18% (3/17) of samples with integrated HPV-16 forms
were diagnosed as ASCUS, 44% (14/32) as LSIL, 70% (7/10)
as HSIL and only one (6%, 1/18) of these integrated samples
had a normal cytology (Fig. 2). The presence of integrated
HPV-16 forms in cytological samples was associated with the
severity of anal lesions (p <0.05).
TABLE 3. Assay sensitivity in dis-
criminating HPV physical forms
assessed in artiﬁcial mixtures of
SiHa DNA in episomal DNA sam-
ples at known concentrations
ID sample
EPISOMAL
(mean copies)
INTEGRATED
(mean SiHA copies)
DCt E6E2
1st RUN 2nd RUN 3rd RUN
1 50 000 10 000 0.62 0.26 0.43
50 000 1000 0.79 0.37 0.11
50 000 100 0.34 0.2 0.08
50 000 10 0.53 0.18 0.05
2 5000 10 000 1.21 2.34 3.05
5000 1000 1.05 1.13 1.26
5000 100 0.43 0.47 0.64
5000 10 0.32 0.17 0.31
3 500 10 000 6.01 7.16 5
500 1000 2.72 5.36 2.5
500 100 1.21 1.1 1.16
500 10 0.32 0.21 0.75
4 100 10 000 7.3 8 8.2
100 1000 3.7 4.34 5
100 100 1.12 1.19 1.8
100 10 0.42 0.23 ND
5 10 10 000 8.42 9.98 ND
10 1000 9 8.01 ND
10 100 4.1 4.03 ND
10 10 1.04 0.96 ND
ND, not done.
DCts (differences in E2 Ct values with regard to E6) obtained in independent measurements of artiﬁcial mixtures of
SiHa DNA in episomal DNA samples at known concentrations, tested in triplicate on three different days.
In bold are relative concentrations where integration is clearly detectable with DCt values of at least 1.
TABLE 2. Variation in DCt, repeatability and reproducibility
of the TaqMan assay for integration of HPV-16
ID
DCt E6E2 (mean ± SD)
Intra-assay Inter-assay
Sample A 0.73 ± 0.22 0.57 ± 0.2
Sample B 0.32 ± 0.15 0.34 ± 0.1
Sample C 0.44 ± 0.24 0.28 ± 0.23
Sample D 0.19 ± 0.15 0.2 ± 0.16
Values are means ± standard deviation (SD) of DCt (differences in Ct values of
E2 with regard to E6). The values are based on independent measurements of
episomal samples by testing four cases in triplicate on different days.
Values up to 1 are considered to indicate integrated forms.
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Discussion
This is a report of the most extensive study of HPV-16 inte-
gration prevalence, by means of a new multiplex real-time
PCR, in anal cell samples of HIV-1-infected men with no pre-
vious history of anal pathology.
Given that integration could be a useful biomarker for can-
cer progression, optimized assays are needed to determine
the value of real-time detection of HPV integration in longitu-
dinal studies. This approach is only possible with a high-
throughput assay that allows the analysis of large sample sizes.
In this study, a new and sensitive real-time PCR method was
used to analyse integration, although other real-time PCR
methods have recently been used in some studies [10,13–18].
All methods used up to now have been based on two sepa-
rate real-time PCR quantiﬁcations of HPV-16 E2 and E6
genes. In previous real-time PCR methods, total viral load
was assessed by E6 quantiﬁcation and the integration was
calculated by quantifying the E2 gene in the same sample and
comparing the different amounts determined. A cut-off based
on the E2/E6 ratio values was then established to assess the
status of episomal, integrated or mixed forms. However,
these procedures presented several drawbacks [9,11–20].
First, different cut-off values have been used, producing mixed
and ambiguous results. Second, the PCR measurement of two
independent sequences ampliﬁed in different reactions can be
hampered by several factors, e.g. the relative concentration
of the initial targets, the different PCR efﬁciencies with differ-
ent primer pairs, and human pipetting errors that, even if
small, could greatly alter the ﬁnal results. In order to mini-
mize these limitations, common strategies were carried out:
(i) accurately measuring the DNA amount used as PCR input,
(ii) running samples in duplicate or triplicate and, ﬁnally, (iii)
assessing cut-off values between separately quantiﬁed
sequences. Despite these approaches, real-time PCR analysis
of HPV integrations produced non-reproducible results.
Ideally, the most accurate way to quantify two viral genes
independently from their relative amounts in the initial tem-
plate and from possible run-to-run variation as a result of
human error would be the simultaneous ampliﬁcation in the
same PCR followed by a relative quantiﬁcation. In this way,
possible changes affecting PCR efﬁciency would have the same
effect on both sequences, thus not inﬂuencing the ﬁnal result.
We developed a new single-tube multiplex real-time PCR that
allowed simple and sensitive detection of integrated forms
without the need for prior accurate DNA quantiﬁcation. HPV
integration is easily detected as an increase in the E2 Ct value
if compared with E6 ampliﬁed in the same PCR.
Spiking experiments with different proportions of SiHa
cells in episomal samples also allowed us to assess the suit-
ability of the assay to discriminate mixed from episomal
forms even if integration was present in only one-ﬁfth of the
total template, which is an improvement over previously
reported data [21].
The prevalence of integration detected in normal anal cyto-
logical analysis is lower (6%, one positive sample out of 18)
than previously observed in cervical samples, where over 50%
of cases with normal cytology have been reported with HPV
integration [13,15,16]. These data also raised concerns about
the clinical signiﬁcance of HPV integration being observed in
such a high proportion of normal samples [21]. Nevertheless,
a recent re-analysis of cut-off values has been introduced and
changes in interpretation of the results may suggest an over-
estimation of integrated forms in a high proportion of cases,
which ideally should lead to a revision of previously reported
data [22]. On the other hand, given that a unique positive
result of integration in a sample with normal cytological
diagnosis could represent a false-negative cytological result,
our results are in agreement with data reported on cervical
samples that were tested using alternative molecular methods
such as ampliﬁcation of papillomavirus oncogne transcripts or
Southern blotting where no integration has been detected in
samples with normal cytology [6,9].
The prevalence of integration (32%) was similar to that
found in the only available study reporting 25% integrated
forms in anal lesions from men in a small subset of 16
patients [21]. Interestingly, in the same study, a strong corre-
lation between HPV-16 status and the presence of chromo-
some copy-number abnormalities (CNAs) has also been
reported, conﬁrming the hypothesis that integration may lead
to increased chromosomal instability as a result of the loss
of E2-mediated repression of E6 and E7 expression. In fact,
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FIG. 2. Frequency distribution of HPV-16 DNA physical state in anal
cytological samples kept in PreservCyt/ThinPrep solutions. ASCUS,
atypical squamous cells of uncertain signiﬁcance (n ¼ 17); LSIL, low-
grade squamous intraepithelial lesions (n ¼ 32); HSIL, high-grade
squamous intraepithelial lesions (n ¼ 10).
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we have observed HPV integration in only 70% of high grade
anal lesions. This may be because of viral DNA disruption
outside the E2 region targeted by our assay. As a conse-
quence, the prevalence of HPV-16 integration could be
underestimated. Recently, this has been shown to be the
most likely sequence to be disrupted during integration
[20]. Therefore, alternative mechanisms to HPV integration
(methylation in host cells or in the HPV genome, environ-
mental factors and pharmacological treatments) could
directly affect gene expression leading, to DNA instability
and ﬁnally to cancer progression.
Longitudinal studies with large sample sizes are necessary
to determine the importance of the physical status of HPV-
16 as a predictive marker for cancer progression, and this
approach will only be possible with a high-throughput
method. Moreover, high-resolution anoscopy has been
shown to be a more sensitive tool for diagnosing high-grade
anal neoplasia [23]. In this context, HPV-16 integration
should be tested in anal biopsies. The multiplex real-time
PCR assay developed in the course of this study was shown
to be a simple, sensitive, speciﬁc and inexpensive technique
which allows the detection of forms of HPV-16 integration
using routinely collected samples.
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